<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Med Biol Res</journal-id><journal-id journal-id-type="iso-abbrev">Braz. J. Med. Biol. Res</journal-id><journal-title-group><journal-title>Brazilian Journal of Medical and Biological Research</journal-title></journal-title-group><issn pub-type="ppub">0100-879X</issn><issn pub-type="epub">1414-431X</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Divulga&#x000e7;&#x000e3;o Cient&#x000ed;fica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25714882</article-id><article-id pub-id-type="pmc">4418367</article-id><article-id pub-id-type="doi">10.1590/1414-431X20143467</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Investigation</subject></subj-group></article-categories><title-group><article-title>Effect of L-carnitine on exercise performance in patients with mitochondrial myopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gimenes</surname><given-names>A.C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bravo</surname><given-names>D.M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>N&#x000e1;polis</surname><given-names>L.M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mello</surname><given-names>M.T.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>A.S.B.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Neder</surname><given-names>J.A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nery</surname><given-names>L.E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Setor de Fun&#x000e7;&#x000e3;o Pulmonar e Fisiologia Cl&#x000ed;nica do Exerc&#x000ed;cio,
Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, <country>Brasil</country></aff><aff id="aff2"><label>2</label>Departamento de Psicobiologia, Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o
Paulo, SP, <country>Brasil</country></aff><aff id="aff3"><label>3</label>Setor de Doen&#x000e7;as Neuromusculares, Universidade Federal de S&#x000e3;o Paulo,
S&#x000e3;o Paulo, SP, <country>Brasil</country></aff></contrib-group><author-notes><corresp>Correspondence: A.C. Gimenes: &#x0003c;<email>anacgimenes@uol.com.br</email>&#x0003e;,
L.E. Nery: &#x0003c;<email>lenery@pneumo.epm</email>&#x0003e;.</corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>24</day><month>2</month><year>2015</year></pub-date><volume>48</volume><issue>4</issue><fpage>354</fpage><lpage>362</lpage><history><date date-type="received"><day>30</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>Exercise intolerance due to impaired oxidative metabolism is a prominent symptom in
patients with mitochondrial myopathy (MM), but it is still uncertain whether
L-carnitine supplementation is beneficial for patients with MM. The aim of our study
was to investigate the effects of L-carnitine on exercise performance in MM. Twelve
MM subjects (mean age&#x000b1;SD=35.4&#x000b1;10.8 years) with chronic progressive external
ophthalmoplegia (CPEO) were first compared to 10 healthy controls (mean age&#x000b1;SD=29&#x000b1;7.8
years) before they were randomly assigned to receive L-carnitine supplementation (3
g/daily) or placebo in a double-blind crossover design. Clinical status, body
composition, respiratory function tests, peripheral muscle strength (isokinetic and
isometric torque) and cardiopulmonary exercise tests (incremental to peak exercise
and at 70% of maximal), constant work rate (CWR) exercise test, to the limit of
tolerance [Tlim]) were assessed after 2 months of L-carnitine/placebo administration.
Patients with MM presented with lower mean height, total body weight, fat-free mass,
and peripheral muscle strength compared to controls in the pre-test evaluation. After
L-carnitine supplementation, the patients with MM significantly improved their Tlim
(14&#x000b1;1.9 <italic>vs</italic> 11&#x000b1;1.4 min) and oxygen consumption (<inline-formula id="bjb-00-00-000-e001"><mml:math id="eq01"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) at CWR exercise, both at isotime (1151&#x000b1;115 <italic>vs</italic>
1049&#x000b1;104 mL/min) and at Tlim (1223&#x000b1;114 <italic>vs</italic> 1060&#x000b1;108 mL/min). These
results indicate that L-carnitine supplementation may improve aerobic capacity and
exercise tolerance during high-intensity CWRs in MM patients with CPEO.</p></abstract><kwd-group><kwd>Exercise tolerance</kwd><kwd>Muscle strength</kwd><kwd>Mitochondrial myopathy</kwd><kwd>L-carnitine supplementation</kwd></kwd-group><counts><fig-count count="1"/><table-count count="6"/><equation-count count="0"/><ref-count count="38"/><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Mitochondrial diseases caused by mutations in nuclear and mitochondrial DNA (mtDNA) are
recognized as the most common types of inherited neuromuscular diseases. These genetic
defects in oxidative phosphorylation lead to specific abnormalities in exercise
performance, such as a reduced maximal whole-body oxygen consumption and elevated
lactate levels during exercise (<xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B02" ref-type="bibr">2</xref>).</p><p>Exercise intolerance, particularly in the form of chronic progressive external
ophthalmoplegia (CPEO), is a very common symptom in individuals with mitochondrial
myopathy (MM) and is typically associated with undue fatigue at relatively low exertion
levels (<xref rid="B03" ref-type="bibr">3</xref>). The most prominent symptoms come from
skeletal muscle, due to their lower oxidative capacity and significant levels of mutant
mtDNA compared with other tissues. Impaired oxidative phosphorylation may result in
exercise intolerance breathlessness, exaggerated lactic acidosis, and low exercise
capacity (<xref rid="B04" ref-type="bibr">4</xref>). This effect may augment the
patient's functional limitations and lead to a vicious cycle of exercise intolerance
exacerbation (<xref rid="B04" ref-type="bibr">4</xref>).</p><p>Although there is no specific therapy for MM (<xref rid="B05" ref-type="bibr">5</xref>,<xref rid="B06" ref-type="bibr">6</xref>), L-carnitine, an amine
administered as a dietary supplement, has been reported to increase the influx of fatty
acids into the mitochondria, facilitating pyruvate oxidation and reducing lactate
synthesis (<xref rid="B07" ref-type="bibr">7</xref>). There is currently no available
disease-modifying therapy for MM. Several agents, mostly nutritional supplements,
including L-carnitine, have been investigated with double-blind, placebo-controlled
studies, but none has demonstrated effects in clinical disease end-points, although
numerous non-blind studies and case reports have suggested that it is beneficial (<xref rid="B08" ref-type="bibr">8</xref>).</p><p>Thus, the purpose of the present study was to determine whether L-carnitine can improve
exercise tolerance in MM subjects. The central hypothesis was that the supplement would
induce physiological changes by increasing oxidative metabolism, resulting in beneficial
effects on skeletal muscle performance and exercise tolerance in these patients.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><p>Twelve patients with biopsy-proven MM followed at the Neuromuscular Division of the
Escola Paulista de Medicina at the Universidade Federal de S&#x000e3;o Paulo (Unifesp) agreed to
participate in the study. Patients were diagnosed after clinical and biopsy evaluation.
The muscle biopsy was obtained from the right vastus lateralis at least 3 months before
the beginning of the study protocol. Samples were frozen in isopentane cooled by liquid
nitrogen for histological and histocytochemical analysis. All muscle biopsies exhibited
abnormal mitochondrial proliferation as ragged red fibers under modified Gomori
trichrome stain and succinate dehydrogenase staining, and as cytochrome c
oxidase-deficient or negative fibers, as well as mosaic patterns dominated by type 1
fibers (<xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B09" ref-type="bibr">9</xref>).</p><p>The inclusion criteria for the trial were: i) MM with CPEO; ii) age &#x0003e;14 years; and
iii) complaint of exercise intolerance, mild fixed limb weakness, or myalgias. The
exclusion criteria were: i) cardiac pacemaker; ii) severe limb weakness; iii)
concomitant ergogenic supplementation treatment; iv) renal, cardiac, or pulmonary
dysfunction; or v) participation in regular physical activity in the preceding year.</p><p>Written informed consent was obtained from all patients, and the study protocol was
approved by the Ethics Committee of the Universidade Federal de S&#x000e3;o Paulo
(#0943/03).</p><p>Ten age- and gender-matched healthy volunteers constituted the control group. To match
the habitual physical activities of the patients, controls were required to have very
low daily physical activity scores as determined by the Baecke questionnaire (a total
score of &#x0003c;6) (<xref rid="B10" ref-type="bibr">10</xref>).</p><sec><title>Study protocol</title><p>The study protocol for MM patients followed a double-blind placebo/L-carnitine
controlled crossover design. Before entering the study, all patients were evaluated
for compliance of the proposed tests (pre-test evaluation). Control subjects did not
receive any supplementary intervention and were only evaluated at the beginning of
the study with the same tests, excluding the constant work rate (CWR) exercise test
(<xref ref-type="fig" rid="f01">Figure 1</xref>). For the double-blind trial,
enrolled patients were randomly assigned to receive either 3 g L-carnitine or 3 g
placebo in one daily dose (with breakfast or lunch) for 8 weeks. They took
identical-looking capsules (DrogaDerma, Brazil). The second evaluation was performed
8 weeks after the patients had received either L-carnitine or placebo. After that, a
4-week washout period was carried out to minimize the drug effect and the third
evaluation was performed after L-carnitine/placebo crossover (<xref ref-type="fig" rid="f01">Figure 1</xref>). Most studies that administered L-carnitine to patients
with chronic diseases utilized daily doses between 2 and 4 g (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>). The 3-g dose given
in this study has been used empirically in the Neuromuscular Division of the Escola
Paulista de Medicina, Unifesp.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Design of study protocol. MM: mitochondrial myopathy; ICPET: incremental
cardiopulmonary exercise test; CWR: constant work rate.</title></caption><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gf001"/></fig><p>Treatment adherence was confirmed by the patient during weekly phone calls and
monthly appointments at the outpatient respiratory clinic. In these consultations,
patients were asked to bring their empty bottles of L-carnitine and receive a new
monthly supplement supply. They also reported possible side effects attributed to the
supplement or placebo. The patients had 100% compliance with the protocol, and no
patient dropped out during the study.</p></sec><sec><title>Measurements</title><sec><title>Body composition</title><p>The patient's mid-arm circumference was measured, and the skin fold thicknesses at
the bicipital and tricipital levels were obtained using a skin-fold caliper. The
arm muscle circumference (cm) was derived from these readings. Bioelectrical
impedance (Quantum BIA-101Q, RJL-101&#x02122;, USA) was used to estimate the total body
fat-free mass (FFM, kg). The FFM index (FFMI) was calculated as the ratio of the
patient's FFM to his or her height (m<sup>2</sup>).</p></sec><sec><title>Pulmonary function testing</title><p>Spirometry lung volumes and maximal voluntary ventilation (MVV) were obtained in
all subjects (Elite series, Medical Graphics Co. [MGC], USA). Data are reported as
a percentage of the predicted values obtained in healthy Brazilian subjects (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B15" ref-type="bibr">15</xref>).</p></sec><sec><title>Cardiopulmonary exercise testing (CPET)</title><p>Incremental cardiopulmonary exercise tests (ICPET) were performed using an
electromagnetically braked cycle ergometer (CPE 2000, MGC). The gas exchange,
ventilator and cardiovascular variables were analyzed breath-by-breath
(CardiO<sub>2</sub> System, MGC) during an ICPET following a linear &#x0201c;ramp&#x0201d;
pattern of increase (<xref rid="B16" ref-type="bibr">16</xref>): 5-15 W/min and
15-25 W/min in patients and healthy subjects, respectively. This protocol was
designed such that the test time was more than 8 min and less than 12 min, based
on &#x0201c;symptom-limited interruption&#x0201d; for all the participants. The following
variables were reported as 15-s means: oxygen uptake (<inline-formula id="bjb-00-00-000-e002"><mml:math id="eq02"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> in mL/min), carbon dioxide output (<inline-formula id="bjb-00-00-000-e003"><mml:math id="eq03"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> in mL/min), minute ventilation (<inline-formula id="bjb-00-00-000-e004"><mml:math id="eq04"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>
<sc>E</sc> in L/min), and the end-tidal partial pressures of oxygen and carbon
dioxide (P<sc>ET</sc>O<sub>2</sub> and P<sc>ET</sc>CO<sub>2</sub>, mmHg). Subject
heart rate (HR, bpm) was automatically calculated from the R-R distance obtained
with 12-lead electrocardiogram tracing (CardiO<sub>2</sub> System, MGC). The
<inline-formula id="bjb-00-00-000-e005"><mml:math id="eq05"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> at the estimated lactate threshold was evaluated using the
gas-exchange threshold (GET) (<xref rid="B17" ref-type="bibr">17</xref>). The
average <inline-formula id="bjb-00-00-000-e006"><mml:math id="eq06"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> in the last 15 s of exercise was considered representative of
the subject's peak <inline-formula id="bjb-00-00-000-e007"><mml:math id="eq07"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> (<xref rid="B18" ref-type="bibr">18</xref>). On a different day,
patients also underwent a CWR exercise test on a cycle ergometer with a load
corresponding to 70% of that obtained in the peak exercise to their limit of
tolerance (Tlim).</p></sec><sec><title>Blood lactate</title><p>Blood samples from the earlobe were collected at peak of the ICPET and in the 5th
min of the recovery period after L-carnitine or placebo treatment. These samples
were analyzed on a lactimeter YSI model 1500 Sport (Yellow Springs Inc., USA)
using an electro-enzymatic method.</p></sec><sec><title>Peripheral muscle testing</title><p>The isokinetic muscle endurance of the dominant knee extensor (quadriceps) was
measured using a computer-based dynamometer (Contrex CE, Switzerland). The subject
was seated upright on the dynamometer chair, with his or her back fully supported.
The lever arm's mechanical axis of rotation was aligned with the knee's axis of
rotation. Muscle strength (a concentric evaluation of the knee's flexion and
extension movements) was determined from the peak torque (PT) measured during five
consecutive maximal repetitions at an angular velocity at 60&#x000b0;/s. Isometric torque
(IT) was evaluated from the maximal knee strength sustained for 5 s at 60&#x000b0;. The
endurance of the quadriceps was determined as the total work (TW) achieved during
20 consecutive maximal repetitions at an angular velocity of 300&#x000b0;/s (<xref rid="B19" ref-type="bibr">19</xref>).</p></sec></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS 15.0 for Windows (USA). To compare data
from controls with the placebo data of patients, we utilized <italic>t</italic>-tests
for independent samples, and the results are reported as means and standard
deviations. For comparison of the effect of placebo and L-carnitine in the patient
group, a crossover trial was performed using a generalized linear mixed model (GLM)
design based on repeated measures to account for treatment and carry-over effects
(placebo&#x02192;L-carnitine <italic>vs</italic> L-carnitine&#x02192;placebo) (<xref ref-type="fig" rid="f01">Figure 1</xref>). For this analysis, we performed Mauchly's test of
sphericity, and when this was not met, we applied the Huynh correction (<xref rid="B20" ref-type="bibr">20</xref>). In case of no influence of the intervention
sequence, the randomized patients were analyzed as a single group (n=12).</p></sec></sec><sec sec-type="results"><title>Results</title><p>During pre-test assessment, patients with MM were found to have lower weight, height,
body mass index and FFMI, compared to normal subjects (P&#x0003c;0.05, <xref ref-type="table" rid="t01">Table 1</xref>). The residual volume (RV; % predicted) was significantly
increased, and the MVV (% predicted) was significantly lower in patients compared to
controls. Patients also presented significantly lower peak torque, isometric torque, and
total work (<xref ref-type="table" rid="t02">Table 2</xref>).</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt001"/></table-wrap>
</p><p>
<table-wrap id="t02" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt002"/></table-wrap>
</p><p>We also observed that peak <inline-formula id="bjb-00-00-000-e008"><mml:math id="eq08"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> (in mL/min and as a % predicted), peak work rate, and GET were
significantly lower in patients compared to controls (<xref ref-type="table" rid="t03">Table 3</xref>). At peak exercise, patients with MM predominantly reported leg
fatigue as evaluated by the Borg scale for lower limbs (<xref ref-type="table" rid="t03">Table 3</xref>).</p><p>
<table-wrap id="t03" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt003"/></table-wrap>
</p><p>No anthropometric or peripheral muscle test differences were observed after L-carnitine
supplementation, compared to patients who received placebo (<xref ref-type="table" rid="t04">Table 4</xref>). Furthermore, MM subjects maintained the same body mass
index, FFM, FFMI, and arm muscle circumference. However, we did find a significant
improvement in inspiratory capacity, both in absolute and % predicted, after L-carnitine
supplementation.</p><p>
<table-wrap id="t04" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt004"/></table-wrap>
</p><p>With regard to the ICPET, no significant differences of metabolic, ventilator, or
cardiovascular variables were detected comparing the studied interventions in the
patient group (<xref ref-type="table" rid="t05">Table 5</xref>). In contrast, during CWR
symptom-limited exercise testing (<xref ref-type="table" rid="t06">Table 6</xref>), we
observed a significantly longer Tlim, higher <inline-formula id="bjb-00-00-000-e009"><mml:math id="eq09"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> at the 6th min of exercise (isotime) and at Tlim after L-carnitine
supplementation compared to the placebo. We also observed a significantly higher oxygen
pulse (<inline-formula id="bjb-00-00-000-e010"><mml:math id="eq10"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>/HR, mL/beat) value at Tlim after L-carnitine compared to placebo.
Importantly, at isotime, the gas-exchange ratio was lower after L-carnitine compared to
placebo.</p><p>
<table-wrap id="t05" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt005"/></table-wrap>
</p><p>
<table-wrap id="t06" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-04-00354-gt006"/></table-wrap>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In the evaluation of the physiological responses after a double-blind
placebo/L-carnitine crossover design in patients with MM, we observed that L-carnitine
(3 g/day) improved aerobic capacity and exercise tolerance during a high-intensity
constant-work exercise in a select group of MM patients with CPEO.</p><sec><title>Clinical characteristics and resting pulmonary function of patients with
MM</title><p>As previously reported (<xref rid="B21" ref-type="bibr">21</xref>), our patients had
lower weight, height, and muscle mass compared to controls and a significantly higher
mean RV, RV to total lung capacity ratio, and reduced MVV compared to controls. These
findings might be related to a restrictive ventilatory pattern that is commonly
observed in patients with neuromuscular diseases (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>In the peripheral muscle evaluation, our patients exhibited significantly less muscle
strength than controls, suggesting that the reduction in peripheral muscle strength
might be related to alterations in oxidative phosphorylation, which is the hallmark
characteristic of these patients (<xref rid="B04" ref-type="bibr">4</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>).
Our patients also showed significantly lower maximum exercise capacity and peak
<inline-formula id="bjb-00-00-000-e011"><mml:math id="eq11"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> compared to controls. Several studies evaluating exercise tolerance
in MM have demonstrated markedly low <inline-formula id="bjb-00-00-000-e012"><mml:math id="eq12"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> peak (<xref rid="B23" ref-type="bibr">23</xref>-<xref rid="B27" ref-type="bibr">27</xref>), reflecting impaired muscle mitochondrial
oxidative phosphorylation. The maximal exercise capacity of MM subjects has been
shown to directly correlate with the degree of O<sub>2</sub> extraction in the
impaired muscle, which enables the use of the systemic arterial to venous
O<sub>2</sub> difference as a surrogate marker for mitochondrial oxidative
capacity (<xref rid="B03" ref-type="bibr">3</xref>,<xref rid="B04" ref-type="bibr">4</xref>).</p></sec><sec><title>Effect of L-carnitine supplementation on exercise performance in patients with
MM</title><p>After oral supplementation of 3 g of L-carnitine over a 2-month period, we observed a
statistically significant change in the patients' body composition as evaluated by
their body mass index, FFM, and FFMI. To our knowledge, no studies have correlated
changes in body composition with L-carnitine supplementation in patients with MM.
Chazot et al. administered L-carnitine to chronic renal failure patients on dialysis
and also found no changes in the body composition after this period of
supplementation, suggesting that L-carnitine did not influence body weight by
decreasing fat mass (<xref rid="B28" ref-type="bibr">28</xref>).</p><p>No differences in peripheral muscle strength after L-carnitine or placebo
administration were observed, a finding that is in accordance with the results of a
study in uremic patients with muscular atrophy. After 24-week treatment with
L-carnitine (2 g at the end of hemodialysis or twice daily in the dialysis solution),
other studies reported an approximately 7% increase in the diameters of type I and
type IIa fibers, but no marked changes in type IIb fibers (<xref rid="B29" ref-type="bibr">29</xref>-<xref rid="B31" ref-type="bibr">31</xref>). These findings
suggest a specific effect of L-carnitine on oxidative metabolism without causing
muscle hypertrophy (<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>).</p><p>In our study, we observed a higher <inline-formula id="bjb-00-00-000-e013"><mml:math id="eq13"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> at Tlim and isotime during constant work exercise, and these
findings were associated with significantly lower gas-exchange ratio values. This
result supports our hypothesis that L-carnitine supplementation increases muscle
oxidative activity in patients with MM. Similarly, Gorostiaga et al. (<xref rid="B33" ref-type="bibr">33</xref>) demonstrated that endurance athletes
supplemented with a daily dose of 2 g of L-carnitine for 28 days had significantly
lower values for gas-exchange ratio during a 66% of maximal CWR exercise, on a
cycloergometer. They suggested that the lower gas-exchange ratio values after
L-carnitine were related to increased lipid utilization by peripheral muscles during
exercise (<xref rid="B33" ref-type="bibr">33</xref>). Our hypothesis for the increase
in the CWR at Tlim and the increase of <inline-formula id="bjb-00-00-000-e014"><mml:math id="eq14"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mtext>V</mml:mtext><mml:mo>&#x002d9;</mml:mo></mml:mover><mml:mtext>O</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> at both isotime and Tlim is that L-carnitine optimizes glucose
utilization during high-intensity exercise. Under these conditions, carnitine could
remove the excess acetyl groups that are formed during increased pyruvate oxidation,
which predominantly occurs in type I muscle fibers. These effects maintain
tricarboxylic acid cycle reactions and increase oxidative metabolism (<xref rid="B34" ref-type="bibr">34</xref>-<xref rid="B36" ref-type="bibr">36</xref>),
which translated into an increased Tlim in our patients. In addition, high-intensity
exercise, both in normal and MM subjects, has been found to reduce muscle carnitine
concentration by two mechanisms: i) the high rate of acylcarnitine formation (<xref rid="B07" ref-type="bibr">7</xref>,<xref rid="B36" ref-type="bibr">36</xref>) and
ii) increased metabolic oxidation of fatty acids (<xref rid="B07" ref-type="bibr">7</xref>). Indeed, up to an 85% reduction in muscle carnitine levels has been
reported in patients with MM (<xref rid="B07" ref-type="bibr">7</xref>,<xref rid="B37" ref-type="bibr">37</xref>). Other studies have shown that in diseases
with a primary or secondary carnitine deficiency, fatty acid oxidation occurs
normally at rest but dramatically declines during prolonged exercise (cycloergometry)
(<xref rid="B34" ref-type="bibr">34</xref>).</p><p>In conclusion, our findings suggest that at a higher rate of fatty acid utilization,
L-carnitine supplementation was associated with a reduction in glucose metabolism,
thus preserving glycogen content and ensuring maximum adenosine triphosphate
oxidation rates. This was associated with fatigue reduction and improved exercise
performance (<xref rid="B07" ref-type="bibr">7</xref>,<xref rid="B37" ref-type="bibr">37</xref>).</p></sec><sec><title>Study limitations</title><p>The results of this study should only be applied to patients with MM and with CPEO
who are without evidence of cardiovascular manifestations or a more severe form of
the disease. In this regard, our patients were selected on the basis of a
histopathological and clinical evaluation; their genotypic changes were not
considered. We did not measure their plasma or muscle levels of carnitine, so we do
not know whether these patients actually had a carnitine deficiency and/or how
carnitine was retained in their muscles after supplementation. Another limitation was
the small number of studied patients. However, they had all presented exclusively
with CPEO at the Neuromuscular Diseases Clinic, Unifesp. However, in a <italic>post
hoc</italic> analysis, this sample size resulted in significant power (&#x0003e;80%)
for the principal variable (Tlim) considered in this study (<xref rid="B38" ref-type="bibr">38</xref>).</p><p>Our results indicated that in patients with MM (CPEO form), a 2-month program of
L-carnitine supplementation (3 g/day) led to an improvement in aerobic performance
characterized by: i) longer Tlim during a high-intensity constant-work exercise and
ii) increased O<sub>2</sub> consumption measured at Tlim and isotime.</p><p>The influence of L-carnitine on oxidative metabolism in selected patients with MM
provides insight into the regulation of skeletal muscle fat and carbohydrate
oxidation during exercise. We suggest that these effects should be tested in future
studies of patients with chronic and slowly-progressive muscle diseases such as
MM.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This research was supported by FAPESP (07/55946-5). A.C. Gimenes was supported by CAPES
as an MSC postgraduate fellow. L.E. Nery and J.A. Neder are established investigators
(level II) of CNPq.</p></ack><fn-group><fn fn-type="other"><p>First published online </p></fn></fn-group><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMauro</surname><given-names>S</given-names></name><name><surname>Lamperti</surname><given-names>C</given-names></name></person-group><article-title>Muscle glycogenoses</article-title><source>Muscle Nerve</source><year>2001</year><volume>24</volume><fpage>984</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1002/mus.1103</pub-id><pub-id pub-id-type="pmid">11439374</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMauro</surname><given-names>S</given-names></name><name><surname>Garone</surname><given-names>C</given-names></name></person-group><article-title>Metabolic disorders of fetal life: glycogenoses and
mitochondrial defects of the mitochondrial respiratory chain</article-title><source>Semin Fetal Neonatal Med</source><year>2011</year><volume>16</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2011.04.010</pub-id><pub-id pub-id-type="pmid">21620786</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeppesen</surname><given-names>TD</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Olsen</surname><given-names>DB</given-names></name><name><surname>Wibrand</surname><given-names>F</given-names></name><name><surname>Krag</surname><given-names>T</given-names></name><name><surname>Duno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aerobic training is safe and improves exercise capacity
in patients with mitochondrial myopathy</article-title><source>Brain</source><year>2006</year><volume>129</volume><fpage>3402</fpage><lpage>3412</lpage><pub-id pub-id-type="doi">10.1093/brain/awl149</pub-id><pub-id pub-id-type="pmid">16815877</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taivassalo</surname><given-names>T</given-names></name><name><surname>Haller</surname><given-names>RG</given-names></name></person-group><article-title>Exercise and training in mitochondrial
myopathies</article-title><source>Med Sci Sports Exerc</source><year>2005</year><volume>37</volume><fpage>2094</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1249/01.mss.0000177446.97671.2a</pub-id><pub-id pub-id-type="pmid">16331135</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelini</surname><given-names>C</given-names></name><name><surname>Semplicini</surname><given-names>C</given-names></name></person-group><article-title>Metabolic myopathies: the challenge of new
treatments</article-title><source>Curr Opin Pharmacol</source><year>2010</year><volume>10</volume><fpage>338</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2010.02.006</pub-id><pub-id pub-id-type="pmid">20356791</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarpelli</surname><given-names>M</given-names></name><name><surname>Cotelli</surname><given-names>MS</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Tomelleri</surname><given-names>G</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Baronchelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Current options in the treatment of mitochondrial
diseases</article-title><source>Recent Pat CNS Drug Discov</source><year>2010</year><volume>5</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.2174/157488910793362412</pub-id><pub-id pub-id-type="pmid">20722626</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brass</surname><given-names>EP</given-names></name></person-group><article-title>Supplemental carnitine and exercise</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>72</volume><fpage>618S</fpage><lpage>623S</lpage><pub-id pub-id-type="pmid">10919968</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>G</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><article-title>Diagnosis and treatment of mitochondrial
myopathies</article-title><source>Ann Med</source><year>2013</year><volume>45</volume><fpage>4</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3109/07853890.2011.605389</pub-id><pub-id pub-id-type="pmid">21867371</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>JL</given-names></name><name><surname>Ratnaike</surname><given-names>TE</given-names></name><name><surname>Shang</surname><given-names>E</given-names></name><name><surname>Falkous</surname><given-names>G</given-names></name><name><surname>Blakely</surname><given-names>EL</given-names></name><name><surname>Alston</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Cytochrome c oxidase-intermediate fibres: importance in
understanding the pathogenesis and treatment of mitochondrial
myopathy</article-title><source>Neuromuscul Disord</source><year>2012</year><volume>22</volume><fpage>690</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2012.04.003</pub-id><pub-id pub-id-type="pmid">22647770</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baecke</surname><given-names>JA</given-names></name><name><surname>Burema</surname><given-names>J</given-names></name><name><surname>Frijters</surname><given-names>JE</given-names></name></person-group><article-title>A short questionnaire for the measurement of habitual
physical activity in epidemiological studies</article-title><source>Am J Clin Nutr</source><year>1982</year><volume>36</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">7137077</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Sirtori</surname><given-names>C</given-names></name><name><surname>Peracino</surname><given-names>A</given-names></name><name><surname>Gheorghiade</surname><given-names>M</given-names></name><name><surname>Borum</surname><given-names>P</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Translating the basic knowledge of mitochondrial
functions to metabolic therapy: role of L-carnitine</article-title><source>Transl Res</source><year>2013</year><volume>161</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2012.10.006</pub-id><pub-id pub-id-type="pmid">23138103</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>M</given-names></name><name><surname>Kraft</surname><given-names>K</given-names></name><name><surname>Gartner</surname><given-names>S</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>E</given-names></name><etal/></person-group><article-title>L-Carnitine-supplementation in advanced pancreatic
cancer (CARPAN) - a randomized multicentre trial</article-title><source>Nutr J</source><year>2012</year><volume>11</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/1475-2891-11-52</pub-id><pub-id pub-id-type="pmid">22824168</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>CA</given-names></name></person-group><article-title>Espirometria</article-title><person-group person-group-type="editor"><name><surname>Pereira</surname><given-names>CA</given-names></name><name><surname>Neder</surname><given-names>JA</given-names></name></person-group><source>Diretrizes para testes de fun&#x000e7;&#x000e3;o pulmonar</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name><year>2014</year></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Andreoni</surname><given-names>S</given-names></name><name><surname>Castelo-Filho</surname><given-names>A</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name></person-group><article-title>Reference values for lung function tests. I. Static
volumes</article-title><source>Braz J Med Biol Res</source><year>1999</year><volume>32</volume><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">10412549</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Andreoni</surname><given-names>S</given-names></name><name><surname>Peres</surname><given-names>C</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name></person-group><article-title>Reference values for lung function tests. III. Carbon
monoxide diffusing capacity (transfer factor)</article-title><source>Braz J Med Biol Res</source><year>1999</year><volume>32</volume><fpage>729</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X1999000600008</pub-id><pub-id pub-id-type="pmid">10412551</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whipp</surname><given-names>BJ</given-names></name><name><surname>Davis</surname><given-names>JA</given-names></name><name><surname>Torres</surname><given-names>F</given-names></name><name><surname>Wasserman</surname><given-names>K</given-names></name></person-group><article-title>A test to determine parameters of aerobic function
during exercise</article-title><source>J Appl Physiol Respir Environ Exerc Physiol</source><year>1981</year><volume>50</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">6782055</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaver</surname><given-names>WL</given-names></name><name><surname>Wasserman</surname><given-names>K</given-names></name><name><surname>Whipp</surname><given-names>BJ</given-names></name></person-group><article-title>Bicarbonate buffering of lactic acid generated during
exercise</article-title><source>J Appl Physiol</source><year>1986</year><volume>60</volume><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">3949651</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name><name><surname>Peres</surname><given-names>C</given-names></name><name><surname>Whipp</surname><given-names>BJ</given-names></name></person-group><article-title>Reference values for dynamic responses to incremental
cycle ergometry in males and females aged 20 to 80</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>1481</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.164.8.2103007</pub-id><pub-id pub-id-type="pmid">11704600</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Nery</surname><given-names>LE</given-names></name><name><surname>Shinzato</surname><given-names>GT</given-names></name><name><surname>Andrade</surname><given-names>MS</given-names></name><name><surname>Peres</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name></person-group><article-title>Reference values for concentric knee isokinetic strength
and power in nonathletic men and women from 20 to 80 years old</article-title><source>J Orthop Sports Phys Ther</source><year>1999</year><volume>29</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.2519/jospt.1999.29.2.116</pub-id><pub-id pub-id-type="pmid">10322586</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robey</surname><given-names>RR</given-names></name></person-group><article-title>Reporting point and interval estimates of effect-size
for planned contrasts: fixed within effect analyses of variance</article-title><source>J Fluency Disord</source><year>2004</year><volume>29</volume><fpage>307</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.jfludis.2004.10.005</pub-id><pub-id pub-id-type="pmid">15639083</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roef</surname><given-names>MJ</given-names></name><name><surname>Kalhan</surname><given-names>SC</given-names></name><name><surname>Reijngoud</surname><given-names>DJ</given-names></name><name><surname>De</surname><given-names>MK</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name></person-group><article-title>Lactate disposal via gluconeogenesis is increased during
exercise in patients with mitochondrial myopathy due to complex I
deficiency</article-title><source>Pediatr Res</source><year>2002</year><volume>51</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1203/00006450-200205000-00008</pub-id><pub-id pub-id-type="pmid">11978882</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masdeu</surname><given-names>MJ</given-names></name><name><surname>Ferrer</surname><given-names>A</given-names></name></person-group><article-title>[Series 4: respiratory muscles in neuromuscular diseases
and the chest cavity. The function of respiratory muscles in neuromuscular
diseases]</article-title><source>Arch Bronconeumol</source><year>2003</year><volume>39</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/S0300-2896(03)75354-X</pub-id><pub-id pub-id-type="pmid">12716560</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Weisman</surname><given-names>IM</given-names></name><name><surname>Zeballos</surname><given-names>RJ</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group><article-title>The role of cardiopulmonary exercise testing for
patients with suspected metabolic myopathies and other neuromuscular
disorders</article-title><person-group person-group-type="editor"><name><surname>Weisman</surname><given-names>IM</given-names></name><name><surname>Zeballos</surname><given-names>RJ</given-names></name></person-group><source>Clinical exercise testing</source><publisher-loc>Basel</publisher-loc><publisher-name>Karger</publisher-name><year>2002</year><fpage>242</fpage><lpage>253</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>BW</given-names></name><name><surname>Fermont</surname><given-names>J</given-names></name><name><surname>Delnooz</surname><given-names>CC</given-names></name><name><surname>Kalkman</surname><given-names>JS</given-names></name><name><surname>Bleijenberg</surname><given-names>G</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name></person-group><article-title>Disease impact in chronic progressive external
ophthalmoplegia: more than meets the eye</article-title><source>Neuromuscul Disord</source><year>2011</year><volume>21</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2010.12.008</pub-id><pub-id pub-id-type="pmid">21236670</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinicke</surname><given-names>K</given-names></name><name><surname>Taivassalo</surname><given-names>T</given-names></name><name><surname>Wyrick</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>H</given-names></name><name><surname>Babb</surname><given-names>TG</given-names></name><name><surname>Haller</surname><given-names>RG</given-names></name></person-group><article-title>Exertional dyspnea in mitochondrial myopathy: clinical
features and physiological mechanisms</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2011</year><volume>301</volume><fpage>R873</fpage><lpage>R884</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00001.2011</pub-id><pub-id pub-id-type="pmid">21813873</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Angelini</surname><given-names>C</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Comi</surname><given-names>GP</given-names></name><name><surname>Minetti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Fatigue and exercise intolerance in mitochondrial
diseases. Literature revision and experience of the Italian Network of
mitochondrial diseases</article-title><source>Neuromuscul Disord</source><year>2012</year><volume>22</volume><issue>(Suppl 3)</issue><fpage>S226</fpage><lpage>S229</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2012.10.012</pub-id><pub-id pub-id-type="pmid">23182644</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimenes</surname><given-names>AC</given-names></name><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Dal Corso</surname><given-names>S</given-names></name><name><surname>Nogueira</surname><given-names>CR</given-names></name><name><surname>Napolis</surname><given-names>L</given-names></name><name><surname>Mello</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Relationship between work rate and oxygen uptake in
mitochondrial myopathy during ramp-incremental exercise</article-title><source>Braz J Med Biol Res</source><year>2011</year><volume>44</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X2011000400013</pub-id><pub-id pub-id-type="pmid">21487644</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chazot</surname><given-names>C</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Hurot</surname><given-names>JM</given-names></name><name><surname>Charra</surname><given-names>B</given-names></name><name><surname>Jean</surname><given-names>G</given-names></name><name><surname>Laurent</surname><given-names>G</given-names></name></person-group><article-title>Nutritional effects of carnitine supplementation in
hemodialysis patients</article-title><source>Clin Nephrol</source><year>2003</year><volume>59</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.5414/CNP59024</pub-id><pub-id pub-id-type="pmid">12572927</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brevetti</surname><given-names>G</given-names></name><name><surname>Chiariello</surname><given-names>M</given-names></name><name><surname>Ferulano</surname><given-names>G</given-names></name><name><surname>Policicchio</surname><given-names>A</given-names></name><name><surname>Nevola</surname><given-names>E</given-names></name><name><surname>Rossini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increases in walking distance in patients with
peripheral vascular disease treated with L-carnitine: a double-blind, cross-over
study</article-title><source>Circulation</source><year>1988</year><volume>77</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.77.4.767</pub-id><pub-id pub-id-type="pmid">3280157</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnoli</surname><given-names>LG</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Mauriello</surname><given-names>A</given-names></name><name><surname>Vacha</surname><given-names>GM</given-names></name><name><surname>D'Iddio</surname><given-names>S</given-names></name><name><surname>Giorcelli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Morphometric evidence of the trophic effect of
L-carnitine on human skeletal muscle</article-title><source>Nephron</source><year>1990</year><volume>55</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1159/000185912</pub-id><pub-id pub-id-type="pmid">2352575</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovenali</surname><given-names>P</given-names></name><name><surname>Fenocchio</surname><given-names>D</given-names></name><name><surname>Montanari</surname><given-names>G</given-names></name><name><surname>Cancellotti</surname><given-names>C</given-names></name><name><surname>D'Iddio</surname><given-names>S</given-names></name><name><surname>Buoncristiani</surname><given-names>U</given-names></name><etal/></person-group><article-title>Selective trophic effect of L-carnitine in type I and
IIa skeletal muscle fibers</article-title><source>Kidney Int</source><year>1994</year><volume>46</volume><fpage>1616</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1038/ki.1994.460</pub-id><pub-id pub-id-type="pmid">7700019</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverio</surname><given-names>R</given-names></name><name><surname>Laviano</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>FF</given-names></name><name><surname>Seelaender</surname><given-names>M</given-names></name></person-group><article-title>l-carnitine and cancer cachexia: Clinical and
experimental aspects</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2011</year><volume>2</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s13539-011-0017-7</pub-id><pub-id pub-id-type="pmid">21475677</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorostiaga</surname><given-names>EM</given-names></name><name><surname>Maurer</surname><given-names>CA</given-names></name><name><surname>Eclache</surname><given-names>JP</given-names></name></person-group><article-title>Decrease in respiratory quotient during exercise
following L-carnitine supplementation</article-title><source>Int J Sports Med</source><year>1989</year><volume>10</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1024895</pub-id><pub-id pub-id-type="pmid">2674034</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>FB</given-names></name><name><surname>Constantin-Teodosiu</surname><given-names>D</given-names></name><name><surname>Greenhaff</surname><given-names>PL</given-names></name></person-group><article-title>New insights concerning the role of carnitine in the
regulation of fuel metabolism in skeletal muscle</article-title><source>J Physiol</source><year>2007</year><volume>581</volume><fpage>431</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.125799</pub-id><pub-id pub-id-type="pmid">17331998</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantin-Teodosiu</surname><given-names>D</given-names></name><name><surname>Carlin</surname><given-names>JI</given-names></name><name><surname>Cederblad</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>RC</given-names></name><name><surname>Hultman</surname><given-names>E</given-names></name></person-group><article-title>Acetyl group accumulation and pyruvate dehydrogenase
activity in human muscle during incremental exercise</article-title><source>Acta Physiol Scand</source><year>1991</year><volume>143</volume><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1111/j.1748-1716.1991.tb09247.x</pub-id><pub-id pub-id-type="pmid">1815472</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantin-Teodosiu</surname><given-names>D</given-names></name><name><surname>Cederblad</surname><given-names>G</given-names></name><name><surname>Hultman</surname><given-names>E</given-names></name></person-group><article-title>PDC activity and acetyl group accumulation in skeletal
muscle during prolonged exercise</article-title><source>J Appl Physiol</source><year>1992</year><volume>73</volume><fpage>2403</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">1490950</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>Y</given-names></name><name><surname>Huertas</surname><given-names>R</given-names></name><name><surname>Lorenzo</surname><given-names>G</given-names></name><name><surname>Bautista</surname><given-names>J</given-names></name><name><surname>Gutierrez</surname><given-names>E</given-names></name><name><surname>Aparicio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma carnitine insufficiency and effectiveness of
L-carnitine therapy in patients with mitochondrial myopathy</article-title><source>Muscle Nerve</source><year>1993</year><volume>16</volume><fpage>150</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1002/mus.880160205</pub-id><pub-id pub-id-type="pmid">8429838</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><source>Statistical power analysis for the behavioral sciences</source><edition>2nd edn</edition><publisher-loc>Hillsdale</publisher-loc><publisher-name>Lawrence Erlbaum Associates</publisher-name><year>1988</year></element-citation></ref></ref-list></back></article>